Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and...

Full description

Saved in:
Bibliographic Details
Main Authors: Goran Medic, Daria Korchagina, Katherine Eve Young, Mondher Toumi, Maarten Jacobus Postma, Micheline Wille, Michiel Hemels
Format: Article
Language:English
Published: MDPI AG 2017-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Rare diseases
orphan drugs
pricing
treatment cost
Europe
Online Access:http://dx.doi.org/10.1080/20016689.2017.1299665
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1080/20016689.2017.1299665

Similar Items